Payment overview · 2025
General Payments
$751.02
28 reported records · 14 companies
Healthcare provider profile · identity verified
Moises Siperstein-Blumovicz, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PORT SAINT LUCIE, FL · NPI 1568436103
Verified facts
What the public records show
CMS Open Payments records show Moises Siperstein-Blumovicz, M.D. received $751.02 in general payments during 2025 across 28 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $165.40 | 22.0% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $138.48 | 18.4% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $119.18 | 15.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $56.65 | 7.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.58 | 6.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.93 | 5.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.98 | 4.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.65 | 3.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.23 | 3.1% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $22.84 | 3.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $22.83 | 3.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.18 | 2.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.62 | 2.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.47 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $751.02 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $142.41 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $138.48 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $129.43 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $56.65 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $51.58 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.58 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.98 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $25.81 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $24.65 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.65 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $22.83 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 216 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 57 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 82 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 30 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
57 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
82 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
216 | 54 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 889 | 278 |
| Atorvastatin Calcium | Atorvastatin Calcium | 653 | 183 |
| Levothyroxine Sodium | Levothyroxine Sodium | 571 | 159 |
| Lisinopril | Lisinopril | 524 | 160 |
| Amlodipine Besylate | Amlodipine Besylate | 491 | 166 |
| Tizanidine Hcl | Tizanidine Hcl | 470 | 165 |
| Meloxicam | Meloxicam | 389 | 153 |
| Alprazolam | Alprazolam | 373 | 84 |
| Omeprazole | Omeprazole | 370 | 116 |
| Losartan Potassium | Losartan Potassium | 348 | 116 |
| Gabapentin | Gabapentin | 313 | 93 |
| Metformin Hcl | Metformin Hcl | 310 | 95 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 298 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 265 | 89 |
| Metoprolol Tartrate | Metoprolol Tartrate | 233 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 228 | 78 |
| Furosemide | Furosemide | 217 | 75 |
| Eliquis | Apixaban | 216 | 54 |
| Trazodone Hcl | Trazodone Hcl | 188 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 178 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 169 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 158 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 157 | 25 |
| Tramadol Hcl | Tramadol Hcl | 152 | 35 |
| Sertraline Hcl | Sertraline Hcl | 142 | 52 |
| Zolpidem Tartrate | Zolpidem Tartrate | 142 | 51 |
| Carvedilol | Carvedilol | 139 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 50 |
| Pregabalin | Pregabalin | 129 | 54 |
| Potassium Chloride | Potassium Chloride | 126 | 40 |
| Glimepiride | Glimepiride | 124 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 121 | 47 |
| Simvastatin | Simvastatin | 118 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 116 | 49 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 115 | 74 |
| Clonazepam | Clonazepam | 113 | 29 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 103 | 83 |
| Donepezil Hcl | Donepezil Hcl | 102 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 32 |
| Atenolol | Atenolol | 95 | 25 |
| Fenofibrate | Fenofibrate | 94 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 94 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 92 | 26 |
| Ezetimibe | Ezetimibe | 88 | 29 |
| Allopurinol | Allopurinol | 83 | 28 |
| Ozempic | Semaglutide | 83 | 22 |
| Ibandronate Sodium | Ibandronate Sodium | 82 | 31 |
| Mounjaro | Tirzepatide | 82 | 19 |
| Methylprednisolone | Methylprednisolone | 77 | 61 |
| Montelukast Sodium | Montelukast Sodium | 77 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 25 |
| Glipizide | Glipizide | 76 | 19 |
| Diazepam | Diazepam | 75 | 27 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 67 | 11 |
| Ketoconazole | Ketoconazole | 67 | 32 |
| Neupro | Rotigotine | 67 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 66 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | 17 |
| Finasteride | Finasteride | 62 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 24 |
| Farxiga | Dapagliflozin Propanediol | 57 | 15 |
| Doxepin Hcl | Doxepin Hcl | 55 | 20 |
| Xarelto | Rivaroxaban | 54 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 16 |
| Lorazepam | Lorazepam | 52 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 16 |
| Alendronate Sodium | Alendronate Sodium | 46 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 14 |
| Sucralfate | Sucralfate | 46 | 18 |
| Synthroid | Levothyroxine Sodium | 46 | 13 |
| Trulicity | Dulaglutide | 46 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 45 | 16 |
| Levetiracetam | Levetiracetam | 45 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 44 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 43 | 33 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 31 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | 13 |
| Memantine Hcl | Memantine Hcl | 40 | 12 |
| Nitroglycerin | Nitroglycerin | 39 | 23 |
| Prednisone | Prednisone | 39 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 19 |
| Famotidine | Famotidine | 38 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | 13 |
| Meclizine Hcl | Meclizine Hcl | 36 | 15 |
| Temazepam | Temazepam | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 31 |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Fentanyl | Fentanyl | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | 12 |
| Topiramate | Topiramate | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Mirtazapine | Mirtazapine | 32 | 15 |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 12 |
| Levofloxacin | Levofloxacin | 31 | 26 |
| Lovastatin | Lovastatin | 31 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 12 |
| Primidone | Primidone | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | 11 |
| Valsartan | Valsartan | 30 | 11 |
| Folic Acid | Folic Acid | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 17 |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Lactulose | Lactulose | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | 21 |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 15 |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 13 |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Dutasteride | Dutasteride | 21 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 21 | 12 |
| Valacyclovir | Valacyclovir Hcl | 21 | 13 |
| Baclofen | Baclofen | 20 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 19 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 18 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Nucynta | Tapentadol Hcl | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $751.02 · 28 records | AstraZeneca Pharmaceuticals LP | AREXVY, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, Korlym, MOUNJARO, NURTEC ODT, OTEZLA, REPATHA, REXULTI, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Wegovy, XIFAXAN, Xhance | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error